House passes spending bill that includes funding for the Children's Health Insurance Program for 6 years; researchers work on an experimental blood test that could detect 8 cancers; President Donald Trump plans to slash the budget of the Office of National Drug Control Policy by as much as 95%.
By a vote of 230 to 197, the House of Representatives passed a spending bill that would a government shutdown. According to The New York Times, the bill provides funding for the Children’s Health Insurance Program (CHIP) for 6 years. However, Senate Republicans are unlikely to sway enough Democratic votes. Democrats want more concessions as part of the spending bill, including a stronger government response to the opioid epidemic and protection for young immigrants brought to the country illegally when they were children.
A blood test in development might be able to detect 8 common cancers in the earliest stages, when those cancers are treatable. Researchers hope that the experimental test—which focuses on breast, colon, esophagus, liver, lung, ovarian, pancreas, and stomach cancers—will only cost $500, reported NPR. The researchers reported that, while the test was only successful 40% of the time in patients with stage 1 cancers, the finding still represents an important milestone in detecting cancers.
The budget of the Office of National Drug Control Policy could be cut by as much as 95%, according to plans from President Donald Trump. The office is responsible for coordinating the government’s response to the opioid crisis, according to Politico. The reduction in funding would mean moving the office’s 2 main grant programs to HHS and the Justice Department. The administration tried to eliminate those grant programs earlier, but received pushback from both parties.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More